ISPAD clinical practice consensus guidelines 2022: Stages of type 1 diabetes in children and
adolescents Page 1 ISPAD GUIDELINES ISPAD clinical practice consensus guidelines 2022 …

Type 1 diabetes is an autoimmune disease caused by the immune-mediated destruction of
pancreatic β cells that results in lifelong absolute insulin deficiency. For nearly a century …

Background Teplizumab, a humanized monoclonal antibody to CD3 on T cells, is approved
by the Food and Drug Administration to delay the onset of clinical type 1 diabetes (stage 3) …

We analyzed the effects of a single 14-day course of teplizumab treatment on metabolic
function and immune cells among participants in a previously reported randomized …

Background Type 1 diabetes is a chronic autoimmune disease that leads to destruction of
insulin-producing beta cells and dependence on exogenous insulin for survival. Some …

Over the past decade, knowledge of the pathogenesis and natural history of type 1 diabetes
has grown substantially, particularly with regard to disease prediction and heterogeneity …

In type 1 diabetes, insulin remains the mature therapeutic cornerstone; yet, the increasing
number of individuals developing type 1 diabetes (predominantly children and adolescents) …

The clinical diagnosis of new-onset type 1 diabetes has, for many years, been considered
relatively straightforward. Recently, however, there is increasing awareness that within this …

OBJECTIVE In November 2022, teplizumab-mzwv became the first drug approved to delay
the onset of stage 3 type 1 diabetes in adults and children age≥ 8 years with stage 2 type 1 …

Restoration of insulin independence and normoglycemia has been the overarching goal in
diabetes research and therapy. While whole-organ and islet transplantation have become …